Enterprise Value
287.1M
Cash
104.8M
Avg Qtr Burn
-10.65M
Short % of Float
2.30%
Insider Ownership
41.87%
Institutional Own.
29.94%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PI-2620 Details Neurological disorder, Alzheimer's disease | Phase 3 Data readout | |
JNJ-2056 (prev. ACI-35.030 or JACI-35.054) (anti-pTau vaccine) Details Neurological disorder, Alzheimer's disease | Phase 2b Data readout | |
ACI-7104.056 Details Parkinson's disease | Phase 2 Data readout | |
Crenezumab Details Alzheimer's disease, Neurological disorder | Phase 2 Update | |
Semorinemab Details Neurological disorder, Alzheimer's disease | Phase 2 Update | |
ACI-24.060 (anti-Abeta vaccine) Details Neurological disorder, Alzheimer's disease, Down Syndrome | Phase 1/2 Data readout | |
AC1-3024 Details Neurological disorder | Failed Discontinued |